WILMINGTON, Del.--(BUSINESS WIRE)--GemPharmatech (GPT) Co., Ltd. announced the establishment of new operations to house more than 6000 mouse models in Massachusetts and California. GPT is a leading global provider of laboratory animals including cKO/KO and humanized mouse models as research tools supporting drug discovery and pre-clinical research and development. Currently, GPT has a large collection of 15,000+ mouse models and has four existing facilities worldwide. The establishment of new operations in the US enables GPT to provide research tools and related services faster and closer to its customers in the R&D communities, including large pharmaceutical and biotech companies, contract research organizations (CROs), universities, and research institutions throughout the US.
“Having our new operations in the US is a critical step in bringing our best products to our customers in the R&D community,” said Dr. Mark Moore, President and CEO of GemPharmatech LLC, a US subsidiary of GemPharmatech Co., Ltd. “With our operations positioned strategically close to our customers, we can interact with our customers better and respond to customers’ requests faster. Our east-coast operation is in the middle of the Boston BioHub with more than 600 pharmaceutical and biotech companies and leading research universities and institutions. Our new operation in California gives us easy access to many top research institutions on the west coast,” continued Dr. Moore.
“Dr. Mark Moore, former Director of the International Mouse Phenotyping Consortium (IMPC), brings years of experience in biomedical research and drug development using animal models to GemPharmatech,” said Dr. Xiang Gao, Chairman of the Board, GemPharmatech, Co., Ltd. “Under his leadership, GemPharmatech is expanding our services to the US and Europe. We are excited to continue our effort in creating novel animal models and helping research communities to dissect the mechanisms of human diseases and accelerate pre-clinical R&D. It is our mission to assist the global effort in developing new drugs to treat diseases and benefit patients,” emphasized Dr. Gao.
GemPharmatech, Co., Ltd. is a leading provider of animal models and services, especially in the development of humanized animal models, to global pre-clinical R&D communities. Its global headquarters is located in Nanjing, China. The Company is specialized in generating mouse models using cutting edge gene-editing technologies with a large collection of conditional knockout (cKO) and knockout (KO) mice, humanized mice, immune deficient mice and germfree mice. GPT provides a one-stop service in model customization, breeding, phenotyping, and pharmacology services including drug efficacy test, pharmacokinetics (PK) service and safety evaluation. The company has developed one of the world's largest collection of over 15,000 different mouse models. GemPharmatech LLC is a wholly owned US subsidiary of GemPharmatech Co., Ltd., with a business office located in Wilmington, Delaware, the heart of “Cellicon Valley” in Biotechnology. Visit http://www.gempharmatech.com for details.